Showing results (151-160 of 277) with videos related to
Sort By:
Pageof 28
Archives of Dermatology|January 19, 2005
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasisAlan Menter, Kenneth Gordon, Wayne Carey, et al.Journal of the American Academy of Dermatology|January 19, 2016
The spectrum of nephrocutaneous diseases and associations: Inflammatory and medication-related nephrocutaneous associationsVanessa L Pascoe, Andrew Z Fenves, Jay Wofford, et al.International Journal of Dermatology|July 9, 2002
A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasisMark Lebwohl, Daniel Sherer, Ken Washenik, et al.Archives of Dermatology|February 20, 2008
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trialAlexa B Kimball, Kenneth B Gordon, Richard G Langley, et al.Journal of the American Academy of Dermatology|May 19, 2015
Phototherapy in dermatology: A call for actionHenry W Lim, Narumol Silpa-archa, Ugochukwu Amadi, et al.Journal of the American Academy of Dermatology|December 15, 2010
Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trialAlexa B Kimball, Kenneth B Gordon, Richard G Langley, et al.Dermatology and Therapy|January 29, 2021
Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated ComorbiditiesAlan Menter, Gerald G Krueger, So Yeon Paek, et al.Biochimica Et Biophysica Acta|February 17, 2012
'Mild mitochondrial uncoupling' induced protection against neuronal excitotoxicity requires AMPK activityPetronela Weisová, Ujval Anilkumar, Caitriona Ryan, et al.Wounds : a Compendium of Clinical Research and Practice|November 23, 2017
Infection-free Clinical Response Among Patients With Hidradenitis Suppurativa Who Were Treated With Adalimumab: Results from Two Phase 3 StudiesEvangelos J Giamarellos-Bourboulis, Jeffrey Sobell, Caitriona Ryan, et al.Journal of Drugs in Dermatology : JDD|August 3, 2007
Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgarisJoel Schlessinger, Alan Menter, Michael Gold, et al.Pageof 28